CLINICAL_TRIALS
trial_result
· 2021-07-21
Clinical Trial Update: A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia [Phase 3]
Summary
Phase 3 long-term safety and tolerability study of ALKS 3831 in adults with schizophrenia completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alkermes, Inc. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2021-07-21